| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Organizational focus on DURAVYUTM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – |
| 19 Oct 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more
WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE) – EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today anno... |
| 19 Oct 2026 |
8-K: Other Events
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – |
| 10 Sep 2026 |
8-K: Other Events
LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1 |
| 17 Aug 2026 |
8-K: Other Events
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYUTM 2.7mg in Wet AMD |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– |
| 30 Jul 2026 |
8-K: Other Events
– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– |
| 17 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
EyePoint Inc. and all subsidiaries and any additional affiliated entities owned, controlled, or operated by EyePoint Inc. including those that may be created during the term of this CIA (collectively, “Entity”) hereby enters into this Co... |
| 22 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, EyePoint, Inc. (the “Company”) maintains the EyePoint, Inc. 2023 Long-Term Incentive Plan, originally effective as of June 20, 2023, as first amended as of June 20, 2024 and as further amended as of June 18, 2025 (as amended, th... |
| 14 May 2026 |
8-K: Other Events
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 – |
| 13 Apr 2026 |
8-K: Other Events
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inacc... |
| 20 Mar 2026 |
8-K: Regulation FD Disclosure
On March 20, 2026, EyePoint, Inc. (the “Company”) filed a complaint against Ocular Therapeutix, Inc. (the “Defendant”) in the Middlesex County Superior Court for the Commonwealth of Massachusetts (the “Complaint”). The Complaint alleges,... |
| 04 Mar 2026 |
8-K: Results of Operations and Financial Condition
Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – |
| 02 Mar 2026 |
8-K: Other Events
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema |
| 07 Jan 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – |
| 08 Dec 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
EyePoint Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), for the purpose of amending its Certificate of Incorporati... |
| 19 Nov 2025 |
8-K: Other Events
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – |
| 06 Nov 2025 |
8-K: Other Events
We are acting as counsel to EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the issuance and sale of up to $200,000,000 of shares of common stock, par value $0.001 per share, of the Company (the... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – |
Loading...